The digital therapeutics developer closed a series B round that included corporate venturing units and existing investors Hikma Ventures and Sanofi Ventures.

Pharmaceutical firms Hikma and Sanofi have participated in a $52m series B round for US-based digital medical treatment developer Click Therapeutics through subsidiaries Hikma Ventures and Sanofi Ventures respectively.

Private equity firm Accelmed co-led the round with asset manager HIG Capital’s HIG BioHealth Partners affiliate. It also featured Health Catalyst Capital, Revelation Partners, K2 HealthVentures, Ridgetop Health and an unnamed biotechnology hedge fund.

Click is developing software to help treat cardiometabolic and autoimmune disorders in addition to psychiatric disorders and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn